(Total Views: 588)
Posted On: 07/26/2021 11:28:54 AM
Post# of 711
![Avatar](https://investorshangout.com/images/ProfileImages/1374810218_8880_DougFairbanks3a.jpg)
Aridis Pharmaceuticals’ COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC)
CoVIC’s animal efficacy data shows that Aridis’ AR-711 mAb is among the top 5 most potent out of more than 350 COVID mAbs that have entered the CoVIC evaluation program to date
The dual mAbs cocktail AR-712 bind to the Delta and Delta Plus variants, and predicted to bind to the Lambda variant as well as all those on the Center for Disease Control’s Variants of Interest and Variants of Concern lists
LOS GATOS, Calif., July 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that animal efficacy data reported by the Coronavirus Immunotherapeutics Consortium (CoVIC) showed that the Company’s COVID-19 monoclonal antibody (mAb) AR-711, one of two mAbs in the AR-712 cocktail, ranks among the top 5 most potent mAbs that the CoVIC consortium have studied to date.
Among a panel of more than 350 therapeutic antibodies identified by different discovery efforts that were submitted for side-by-side analyses by CoVIC, AR-711 had neutralization potency that ranked among the top 10% of the panel (single-digit ng/mL IC50 values in three different neutralization assays). Based on this potency, AR-711 was prioritized for animal efficacy testing by CoVIC. Of the ~75 antibodies tested to date in a mouse model of SARS-CoV-2 infection, the AR-711 mAb was among the top 5 most potent mAbs and effectively protected infected animals at the lowest parenteral dose tested (0.5 mg/kg). The dual antibody cocktail of AR-711 and AR-720 will be delivered as an inhaled treatment, effective against the Delta and Delta Plus variants, and is expected to provide broad coverage of all known high-risk variants.
CoVIC’s animal efficacy data shows that Aridis’ AR-711 mAb is among the top 5 most potent out of more than 350 COVID mAbs that have entered the CoVIC evaluation program to date
The dual mAbs cocktail AR-712 bind to the Delta and Delta Plus variants, and predicted to bind to the Lambda variant as well as all those on the Center for Disease Control’s Variants of Interest and Variants of Concern lists
LOS GATOS, Calif., July 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that animal efficacy data reported by the Coronavirus Immunotherapeutics Consortium (CoVIC) showed that the Company’s COVID-19 monoclonal antibody (mAb) AR-711, one of two mAbs in the AR-712 cocktail, ranks among the top 5 most potent mAbs that the CoVIC consortium have studied to date.
Among a panel of more than 350 therapeutic antibodies identified by different discovery efforts that were submitted for side-by-side analyses by CoVIC, AR-711 had neutralization potency that ranked among the top 10% of the panel (single-digit ng/mL IC50 values in three different neutralization assays). Based on this potency, AR-711 was prioritized for animal efficacy testing by CoVIC. Of the ~75 antibodies tested to date in a mouse model of SARS-CoV-2 infection, the AR-711 mAb was among the top 5 most potent mAbs and effectively protected infected animals at the lowest parenteral dose tested (0.5 mg/kg). The dual antibody cocktail of AR-711 and AR-720 will be delivered as an inhaled treatment, effective against the Delta and Delta Plus variants, and is expected to provide broad coverage of all known high-risk variants.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)